EMEA Looking At Limited Use Of Adaptive Design In Late-Stage Trials
Executive Summary
Adaptive designs are "a contradiction to the confirmatory nature" of Phase III clinical trials, EMEA's Committee for Medicinal Products for Human Use says in a reflection paper
You may also be interested in...
Time To Be Creative With Adaptive Trials May Be Non-Pivotal Portion
BARCELONA, SPAIN - For companies looking to adopt adaptive trial designs, Merck VP of Biostatistics and Research Decision Sciences Jerald Schindler urged sponsors to frontload most of the adaptation in the non-pivotal portion of the clinical trial program and limit their own involvement in the adaptation that does take place during the pivotal portion
Time To Be Creative With Adaptive Trials May Be Non-Pivotal Portion
BARCELONA, SPAIN - For companies looking to adopt adaptive trial designs, Merck VP of Biostatistics and Research Decision Sciences Jerald Schindler urged sponsors to frontload most of the adaptation in the non-pivotal portion of the clinical trial program and limit their own involvement in the adaptation that does take place during the pivotal portion
Late-Stage Trials Pose Challenge As FDA Molds Adaptive Design Guidance
The work group developing FDA's guidance on adaptive clinical trial design is still trying to figure out the complex issues associated with late-stage studies, the Center for Drug Evaluation and Research's "town hall" discussion at the Drug Information Association annual meeting in Atlanta revealed